<DOC>
	<DOCNO>NCT01516957</DOCNO>
	<brief_summary>The study examine safety effectiveness AMG 827 treatment psoriatic arthritis . Patients randomly receive either AMG 827 placebo ( look-a-like liquid drug ) neither doctor patient know treatment give .</brief_summary>
	<brief_title>AMG 827 Subjects With Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Subject diagnosis psoriatic arthritis ( Classification Psoriatic Arthritis ( CASPAR ) criterion ) least 6 month Subject ≥ 3 tender ≥ 3 swollen joint Subject active infection history infection ( systemic antiinfectives use within 28 day ; require hospitalization intravenous antiinfectives within 8 week ; recurrent chronic ) Significant concurrent medical condition Pregnant breast feeding Significant Laboratory abnormality Use sulfasalazine , hydroxychloroquine , systemically administer calcineurin inhibitor , azathioprine , parenteral corticosteroid include intramuscular intraarticular administration , live vaccine within 28 day Use antiTNF therapy within 2 month Use antiinterleukin ( IL ) 12/IL23 drug experimental commercially available biologic therapy psoriasis and/or psoriatic arthritis within 3 month Prior use rituximab Prior use antiIL17 biologic therapy , include AMG 827</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>IL-17</keyword>
	<keyword>AMG 827</keyword>
	<keyword>AMG827</keyword>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>Spondylarthropathy</keyword>
</DOC>